Abstract 1195P
Background
Li-Fraumeni syndrome (LFS) is a rare autosomal dominant condition, caused by an alteration in the TP53 gene. Individuals with LFS are susceptible to developing a wide range of malignancies. National and international guidelines recommend annual WB-MRI scan for screening for cancer; however, WB-MRI is not yet implemented in this setting worldwide or in the UK. SIGNIFIED is a cost-effectiveness and implementation project that will assess the value of screening WB-MRI in LFS.
Methods
Individuals with LFS, with no cancer diagnosis in the past 5 years, were scanned using two WB-MRI, 12 months apart. Diffusion-weighted MRI images were acquired from vertex to feet. Incidental findings were further investigated and discussed in a specialist MDT meeting.
Results
Fifty-four asymptomatic individuals with LFS were recruited between May 2022 and July 2023 from Cancer Genetic Units across the United Kingdom. 40 females (74%) and 14 males (26%) were enrolled. The median age at recruitment was 42 years (range 18-70). Following 1st scan performed in 54 individuals, 16.6% of patients had a suspicious lesion that was biopsied/excised (N=9), and less than half (44%, N=4) had a confirmed cancer. Following 2nd scan performed in 44 individuals, 13.6% of patients had a suspicious lesion that was biopsied/excised (N=6) and in 83% of cases (N=5), a cancer diagnosis was confirmed. There was increased confidence in benignity when a comparator scan was available. In total, 9 cancers were detected and 66% (N=6) were diagnosed at stages 0-2 and underwent curative treatment. A further stage 3 pancreatic cancer (T4N0M0) was diagnosed and the patient received peri-operative chemotherapy and surgery with curative intent.
Conclusions
Overall, 9 cancers in 54 individuals were diagnosed with the help of WB-MRI. The rate of cancers detected in this cohort was higher than expected in a general population, consistent with the known risk of cancers in the LFS population. WB-MRI is a valuable and useful radiological tool for the detection of early cancers in LFS and our data support guidelines that it should be implemented as a regular screening test for this population. A health economics analysis is currently ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Small Business Research Initiative (SBRI) Healthcare.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1181P - Diagnostic target product profiles for cancer: A demand signaling tool to stimulate innovation in early cancer diagnosis
Presenter: Sonja Marjanovic
Session: Poster session 09
1182P - Determination of tumor PSMA expression in prostate cancer from blood using a novel epigenomic liquid biopsy platform
Presenter: Praful Ravi
Session: Poster session 09
1183P - Impact of multicancer early detection (MCED) test on participant-reported outcomes (PRO) and behavioral intentions by cancer risk
Presenter: Christina Dilaveri
Session: Poster session 09
1184P - Early real-world experience with positive multi-cancer early detection (MCED) test cases and negative initial diagnostic work-up
Presenter: Candace Westgate
Session: Poster session 09
1185P - Clinical applications of a novel blood-based fragmentomics assay for lung cancer detection
Presenter: Marc Siegel
Session: Poster session 09
1186P - SmartCS-LPLLM: Enhancing early cancer detection through ctDNA methylation analysis leveraging large language models
Presenter: Li Chao
Session: Poster session 09
1187P - Molecular diagnosis of lung cancer via ctDNA and ctRNA detection on bronchoscopic fluid specimens from 31 patients: A retrospective analysis
Presenter: Vincent Fallet
Session: Poster session 09
1188P - Modeled economic and clinical impact of a multi-cancer early detection (MCED) test in a population with hereditary cancer syndromes
Presenter: Sana Raoof
Session: Poster session 09
1189P - Cancer genome interpreter: A data-driven tool for tumor mutation interpretation
Presenter: Santiago Demajo
Session: Poster session 09
1190P - Circulating tumor DNA from the tumor-draining pulmonary vein as a biomarker in resected non-small cell lung cancer
Presenter: Raphael Werner
Session: Poster session 09